高级混合闭环自动化胰岛素输送系统时代的时间范围内目标的未来。
Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems.
机构信息
Barbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, USA.
University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
出版信息
Diabetes Technol Ther. 2024 Mar;26(S3):102-106. doi: 10.1089/dia.2023.0432.
Abstract
The concept of maintaining blood glucose levels within the 70-180 mg/dL range, known as time-in-range, has raised questions regarding its representation of true physiological euglycemia. Some have speculated that focusing on the time spent within the 70-140 mg/dL range, introduced as time in tight range (TITR) through the International Consensus statement, could serve as a more precise metric for assessing normoglycemia in individuals with type 1 diabetes. This article delves into the current status of TITR as an emerging marker and explores how advanced hybrid closed-loop systems may offer a promising avenue for achieving this higher level of glycemic control.
摘要
将血糖水平维持在 70-180mg/dL 范围内的概念，即时间在范围内，引发了关于其是否真正代表生理血糖正常的问题。有人推测，通过国际共识声明引入的将时间花费在 70-140mg/dL 范围内的时间，即时间在严格范围内（TITR），可能成为评估 1 型糖尿病患者血糖正常的更精确指标。本文深入探讨了 TITR 作为新兴标志物的现状，并探讨了先进的混合闭环系统如何为实现更高水平的血糖控制提供有前途的途径。
相似文献
1
Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems.
Diabetes Technol Ther. 2024 Mar;26(S3):102-106. doi: 10.1089/dia.2023.0432.
2
Time in tight glucose range in adolescents and young adults with diabetes during Ramadan intermittent fasting: Data from real-world users on different treatment strategies.
Diabetes Res Clin Pract. 2025 Mar;221:112042. doi: 10.1016/j.diabres.2025.112042. Epub 2025 Feb 16.
3
Utility of time in tight range (TITR) in evaluating metabolic control in pediatric and adult patients with type 1 diabetes in treatment with advanced hybrid closed-loop systems.
Endocrine. 2024 Nov;86(2):539-545. doi: 10.1007/s12020-024-03881-6. Epub 2024 May 30.
4
Assessing the feasibility of time in tight range (TITR) targets with advanced hybrid closed loop (AHCL) use in children and adolescents: A single-centre real-world study.
Diabet Med. 2024 Aug;41(8):e15333. doi: 10.1111/dme.15333. Epub 2024 Apr 26.
5
Time in tight range: A key metric for optimal glucose control in the era of advanced diabetes technologies and therapeutics.
Diabetes Obes Metab. 2025 Feb;27(2):450-456. doi: 10.1111/dom.16033. Epub 2024 Nov 11.
6
Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling.
Health Technol Assess. 2024 Dec;28(80):1-190. doi: 10.3310/JYPL3536.
7
Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States.
Diabetes Technol Ther. 2024 Mar;26(S3):24-31. doi: 10.1089/dia.2023.0453.
8
Temporary Target Versus Suspended Insulin Infusion in Patients with Type 1 Diabetes Using the MiniMed 780G Advanced Closed-Loop Hybrid System During Aerobic Exercise: A Randomized Crossover Clinical Trial.
Diabetes Technol Ther. 2024 Nov;26(11):823-828. doi: 10.1089/dia.2023.0589. Epub 2024 Sep 30.
9
Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system.
Diabetes Obes Metab. 2023 Jun;25(6):1688-1697. doi: 10.1111/dom.15023. Epub 2023 Mar 13.
10
Aiming for the Best Glycemic Control Beyond Time in Range: Time in Tight Range as a New Continuous Glucose Monitoring Metric in Children and Adolescents with Type 1 Diabetes Using Different Treatment Modalities.
Diabetes Technol Ther. 2024 Mar;26(3):161-166. doi: 10.1089/dia.2023.0373.
引用本文的文献
1
International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024 Diabetes Technologies: Glucose Monitoring.
Horm Res Paediatr. 2024;97(6):615-635. doi: 10.1159/000543156. Epub 2025 Jan 30.
2
Association between time in tight range and incident diabetic retinopathy in adults with type 2 diabetes.
Diabetes Obes Metab. 2025 Mar;27(3):1415-1422. doi: 10.1111/dom.16143. Epub 2024 Dec 18.
3
12-Month Time in Tight Range Improvement with Advanced Hybrid-Closed Loop System in Adults with Type 1 Diabetes.
Diabetes Ther. 2024 Dec;15(12):2557-2568. doi: 10.1007/s13300-024-01656-w. Epub 2024 Sep 30.
4
The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study.
Diabetologia. 2024 Aug;67(8):1527-1535. doi: 10.1007/s00125-024-06171-y. Epub 2024 May 24.
本文引用的文献
1
Emerging Technologies and Therapeutics for Type 1 Diabetes.
Endocrinol Metab Clin North Am. 2024 Mar;53(1):81-91. doi: 10.1016/j.ecl.2023.07.002. Epub 2023 Aug 19.
2
Aiming for the Best Glycemic Control Beyond Time in Range: Time in Tight Range as a New Continuous Glucose Monitoring Metric in Children and Adolescents with Type 1 Diabetes Using Different Treatment Modalities.
Diabetes Technol Ther. 2024 Mar;26(3):161-166. doi: 10.1089/dia.2023.0373.
3
A Comparison of Continuous Glucose Monitoring-Measured Time-in-Range 70-180 mg/dL Versus Time-in-Tight-Range 70-140 mg/dL.
Diabetes Technol Ther. 2024 Mar;26(3):151-155. doi: 10.1089/dia.2023.0380. Epub 2023 Oct 13.
4
Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade.
Diabetes Care. 2023 Sep 1;46(9):1646-1651. doi: 10.2337/dc23-0495.
5
Differential correlation between time in range and eGFR or albuminuria in type 2 diabetes.
Diabetol Metab Syndr. 2023 May 5;15(1):92. doi: 10.1186/s13098-023-01071-4.
6
Time in range as a useful marker for evaluating retinal functional changes in diabetic retinopathy patients.
Int J Ophthalmol. 2023 Jun 18;16(6):915-920. doi: 10.18240/ijo.2023.06.13. eCollection 2023.
7
Beyond A1C: exploring continuous glucose monitoring metrics in managing diabetes.
Endocr Connect. 2023 Jun 26;12(7). doi: 10.1530/EC-23-0085. Print 2023 Jul 1.
8
A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72.
Diabetes Technol Ther. 2023 May;25(5):329-342. doi: 10.1089/dia.2022.0558. Epub 2023 Apr 12.
9
Increased Technology Use Associated With Lower A1C in a Large Pediatric Clinical Population.
Diabetes Care. 2023 Jun 1;46(6):1218-1222. doi: 10.2337/dc22-2121.
10
Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE.
Diabetes Technol Ther. 2023 Jun;25(6):378-383. doi: 10.1089/dia.2022.0447. Epub 2023 May 8.
Zotero 插件